Fajgenbaum David C, Khor Johnson S, Gorzewski Alexander, Tamakloe Mark-Avery, Powers Victoria, Kakkis Joseph J, Repasky Mileva, Taylor Anne, Beschloss Alexander, Hernandez-Miyares Laura, Go Beatrice, Nimgaonkar Vivek, McCarthy Madison S, Kim Casey J, Pai Ruth-Anne Langan, Frankl Sarah, Angelides Philip, Jiang Joanna, Rasheed Rozena, Napier Erin, Mackay Duncan, Pierson Sheila K
Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania, Philadelphia, PA, USA.
Infect Dis Ther. 2020 Sep;9(3):435-449. doi: 10.1007/s40121-020-00303-8. Epub 2020 May 27.
The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID-19 patients published between 1 December 2019 and 27 March 2020. Data were analyzed descriptively. Of the 2706 articles identified, 155 studies met the inclusion criteria, comprising 9152 patients. The cohort was 45.4% female and 98.3% hospitalized, and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There were insufficient data to compare across treatments. Many treatments have been administered to the first 9152 reported cases of COVID-19. These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients at www.CDCN.org/CORONA . Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.
严重急性呼吸综合征冠状病毒2/2019新型冠状病毒（COVID-19）的出现引发了一场全球大流行，目前尚无获批的治疗方法或疫苗。许多治疗方法已应用于COVID-19患者，但尚未得到系统评估。我们进行了一项系统的文献综述，以确定所有报告应用于COVID-19患者的治疗方法，并对有足够数据的治疗方法评估达到临床有意义反应的时间。我们在PubMed、BioRxiv、MedRxiv和中国Xiv上搜索了2019年12月1日至2020年3月27日期间发表的关于COVID-19患者治疗的文章。对数据进行描述性分析。在识别出的2706篇文章中，155项研究符合纳入标准，共9152例患者。队列中女性占45.4%，98.3%为住院患者，平均（标准差）年龄为44.4岁（标准差21.0）。最常使用的药物类别是抗病毒药物、抗生素和皮质类固醇，在报告的115种药物中，最常使用的是洛匹那韦/利托那韦组合，其达到临床有意义反应（症状完全缓解或出院）的时间为11.7（1.09）天。没有足够的数据对不同治疗方法进行比较。许多治疗方法已应用于报告的首批9152例COVID-19病例。这些数据是在www.CDCN.org/CORONA上建立所有报告的COVID-19患者治疗方法开源登记册的基础。需要进一步开展工作，以便在严格控制的临床试验和治疗方案中确定优先研究的药物。
